IMI2 (The Innovative Medicines Initiative) 16th call 2018


Convocatòria tancada
Entitat convocant:
European Commission
Àmbit:
Internacional
Inici:
Termini intern:
Termini real:
Descripció:

Objectiu de la convocatòria


IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA).


The goal of the Innovative Medicines Initiative 2 (IMI 2) is to develop next generation vaccines, medicines and treatments, such as new antibiotics. It will build on the successes and lessons learnt under IMI. Like IMI, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe's growing health challenges, and secure the future international competitiveness of Europe's pharmaceutical industry.

Característiques principals

Topics of the 16th Call:

  • Topic 1: Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for tuberculosis (TB) that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
  • Topic 2: Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs
  • Topic 3: Discover and progress novel assets with new mechanisms of action (one preNME for TB and one preNME for NTM) and biomarkers for TB and NTM infection
  • Topic 4: Determination of gepotidacin levels in tonsils and prostatic tissue
  • Topic 5: Infection site targeting, antibiotic encapsulated in nanoparticles for treating extracellular bacterial infections
  • Topic 6: Functional Ethionamide boosters: a novel combination for tuberculosis therapy
  • Topic 7: Intravenous treatments of serious infections (urinary tract infections (UTI), intra-abdominal infections (IAI) & hospital-acquired pneumonia/ventilator associated pneumonia (HAP/VAP)) caused by Gram(-) bacteria (Enterobacteriaceae +/- Pseudomonas and/or Acinetobacter)

 

Característiques principals

This Call is being run in a single stage submission and evaluation process.

 

Convocatòria (URL)
https://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/calls/h2020-jti-imi2-2018-16-single-stage.html

 

Dotació


IMI JU collaborative projects are implemented through a co-financing scheme. The IMI JU grants financial support to the eligible entities, while the other entities (including the EFPIA companies) participate in the project with their own resources.